Drug Testing Locations - Kingston, NH

Drug Testing in Kingston, NH

Kingston, New Hampshire Statistics

Kingston, NH in Rockingham County saw a 15% increase in opioid-related overdoses in 2022.

In 2021, Rockingham County reported 80 drug-related arrests, some stemming from Kingston incidents.

Kingston's high school reported a slight decrease in student drug use in 2022, according to Rockingham County data.

In 2022, Rockingham County health services noted an uptick in fentanyl presence within Kingston and surrounding areas.

A Rockingham County survey in 2023 found that 30% of Kingston residents perceived drug abuse as a major local issue.

How does the body eliminate Drugs

Drug elimination is the sum of the processes of removing an administered drug from the body. In the pharmacokinetic ADME scheme (absorption, distribution, metabolism, and excretion), it is frequently considered to encompass both metabolism and excretion. Hydrophobic drugs, to be excreted, must undergo metabolic modification making them more polar. Hydrophilic drugs, on the other hand, can undergo excretion directly, without the need for metabolic changes to their molecular structures.

Although many sites of metabolism and excretion exist, the chief organ of metabolism is the liver, while the organ primarily tasked with excretion is the kidney. Any significant dysfunction in either organ can result in the accumulation of the drug or its metabolites in toxic concentrations.

A variety of other factors impact elimination — intrinsic drug properties, such as polarity, size, or pKa. Also other factors include genetic variation among individuals, disease states affecting other organs, and pathways involved in the way the drug distributes through the body, such as first-pass metabolism.

Issues of Concern

Drug elimination is the removal of an administered drug from the body. It is accomplished in two ways, either by excretion of an unmetabolized drug in its intact form or by metabolic biotransformation followed by excretion. While excretion is primarily carried out by the kidneys, other organ systems are involved as well. Similarly, the liver is the primary site of biotransformation, yet extrahepatic metabolism takes place in a variety of organ systems affecting multiple drugs.

Given the multiple organ systems and the variety of metabolic transformations present, drug elimination can entail a significant degree of complexity. Hydrophilic drugs are typically directly excreted by the kidneys, while hydrophobic drugs undergo biotransformation before excretion. The purpose here is twofold – biotransformation serves both detoxify the exogenous substances as well as to increase their hydrophilicity, ensuring their elimination via the kidneys.

Two broad metabolic pathways of hepatic drug transformation exist. Phase I is the direct modification of the target molecule, whereas phase II entails conjugation of the target to a polar molecule of low molecular weight. Phase I prepare the drug to enter phase II, but single-phase metabolism also exists.

Phase I involves oxidation, reduction, and hydrolysis of the exogenous molecule. These reactions are accomplished by hepatic microsomal enzymes, which reside in the smooth endoplasmic reticulum of the hepatocytes. Best known among them is the cytochrome P450 system, whose enzymes are predominantly involved in oxidative metabolism. Within the cytochrome P450 family (CYP), the enzyme responsible for the metabolism of more than 50% of existing drugs is the CYP3A4. Its activity encompasses various classes of medications, including opioids, immunosuppressants, antihistamines, and benzodiazepines. The enzymes can also be induced or inhibited by a variety of substances they interact with, including pharmaceuticals. The increase in metabolic activity with CYP induction results in a diminished activity of drugs targeted by that particular isoform. Conversely, CYP inhibition will result in increased drug plasma concentration, potentially leading toxicity. The CYP3A4 is induced by phenytoin, phenobarbital, and St. John's wort, while diltiazem, erythromycin, and grapefruit inhibit it. Caution is, therefore, necessary when administering CYP3A4-metabolized drugs in the presence of any of the inhibitors or inducers.

Phase II consists of covalent bonding of polar groups to nonpolar molecules to render them water-soluble and allow renal or biliary excretion. Target molecules enter phase II directly or via initial processing through phase I. A variety of polar adjuncts is transferred, including amino acids, glucuronic acid, glutathione, acetate, and sulfate. Glucuronidation is one of the major pathways of phase II biotransformation. The UDP-glucuronosyltransferase (UGT) enzyme family performs this activity. Typically, glucuronide derivatives possess less or no activity of the original drug, but in some cases, pharmacologically active compounds result. Morphine-6-glucuronide is a phase II metabolite of morphine with significant analgesic activity. As with the CYP enzymes, inducers, and inhibitors of phase II, enzymes exist and may influence the efficacy of drugs that rely on conjugation before excretion.

The first-pass effect is a feature of hepatic metabolism that also plays a role in the elimination of multiple drugs. Here, the enteric consumed drugs are exposed directly to the liver via the portal vein, where they undergo biotransformation before entering the systemic circulation. This activity reduces the bioavailability and needs to be factored into the dose administered to the patient. Intravenously administered drugs are not subject to the first-pass effect.

Extrahepatic drug metabolism takes place in the GI tract, kidneys, lungs, plasma, and skin.

Renal excretion completes the process of elimination that begins in the liver. Polar drugs or their metabolites get filtered in the kidneys and typically do not undergo reabsorption. They subsequently get excreted in the urine. Urinary pH has a significant impact on excretion, as drug ionization changes depending on the alkaline or acidic environment. Increased excretion occurs with weakly acidic drugs in basic urine and weakly basic drugs in acidic urine.

Excretion in the bile is another significant form of drug elimination. The liver can actively secrete ionized drugs with a molecular weight greater than 300 g/mol into bile, from where they reach the digestive tract and are either eliminated in feces or reabsorbed as part of the enterohepatic cycle.

Other pathways of excretion include the lungs, breast milk, sweat, saliva, and tears

Employers in Kingston, NH & Drug Testing Policies

Employers in Kingston, NH, recognize the importance of maintaining a drug-free workplace. Many have implemented strict drug testing policies in compliance with state regulations. This includes pre-employment screenings and random drug tests to ensure the safety and productivity of their workforce. Kingston businesses often refer to the guidelines provided by the U.S. Department of Labor for workplace drug testing policies.

Local firms are also encouraged to develop Employee Assistance Programs (EAPs) to support workers struggling with substance abuse. By offering services such as counseling and rehabilitation, Kingston employers aim to foster a supportive and proactive environment that addresses the challenges of drug addiction head-on.

Government Efforts with Drug Problems in Kingston, NH

The government of Kingston, NH, along with Rockingham County officials, has been actively working to address drug problems through various initiatives. Programs such as the New Hampshire Department of Health and Human Services focus on prevention and recovery support. Local law enforcement in Kingston works closely with the New Hampshire Attorney General's Office to tackle drug trafficking and abuse.

Additionally, the state has implemented the Governor's Commission on Alcohol & Drug Abuse Prevention, working to align local efforts with state-wide strategies. Kingston's collaboration with organizations like the Granite Recovery Centers is aimed at enhancing treatment availability, supporting community-based intervention, and expanding educational outreach on substance abuse.

Local Drug Busts & News in Kingston, NH

Kingston, NH, has been the site of several notable drug busts and drug-related events in recent years. For instance, coordinated efforts between local law enforcement and the U.S. Attorney’s Office for the District of New Hampshire have led to successful crackdowns on drug distribution networks within Rockingham County.

Additionally, community drug-awareness events are frequently organized to educate residents on the risks of drug use and encourage local participation in prevention efforts. These events in Kingston often feature collaborations with health professionals, law enforcement, and recovery groups to provide comprehensive support and information.

Occupational Health Services

Accredited Drug Testing offers fast, reliable employment screening services in Kingston, NH. Trusted by employers nationwide for accurate results and exceptional service.

New Hampshire DOT/Non DOT Physicals

New Hampshire Vision Tests

New Hampshire Audiograms

New Hampshire Respirator Fit Tests

New Hampshire Lift Tests

New Hampshire Background Checks

Clinical Testing Services

TB Testing in NH

Diabetes Testing in NH

Infectious Disease Testing in NH

Sickle Cell Anemia Testing in NH

Women/Men's Health Testing in NH

Resources & Citations

New Hampshire Department of Health and Human Services

Granite Recovery Centers

The Youth Council

New Futures

City of Dover

Care New England

Rehab.com

Treatment Insights of New England

Drug Testing Near Kingston, NH

Seabrook Beach, NH

Hampton Beach, NH

Newmarket, NH

Hampton, NH

Seabrook, NH

Stratham, NH

Raymond, NH

Newfields, NH

Atkinson, NH

Hampstead, NH

Plaistow, NH

Epping, NH

Exeter, NH

Frequently Asked Questions

Customer Reviews